GGrantIndex
← Search

SAFETY &EFFICACY OF RECOMBINANT ALPHA GALACTOSIDASE-A

$0M01FY2000RRNIH

Mount Sinai School Of Medicine Of Cuny, New York NY

Investigators

Linked publications & trials

Abstract

This is a multicenter, placebo-controlled, double-blind, randomized study of patients diagnosed with Fabry disease with no prior treatment with alpha-galactosidase A. The purpose of this study is to determine the safety and effectiveness of a manufactured form of the human enzyme known as recombinant human alpha-galactosidase A in the treatment of patients with Fabry disease.

View original record on NIH RePORTER →